Based on the provided source data, I cannot identify specific medications to list, as the trial information doesn’t explicitly mention any medication names. The trial is described as investigating treatments for Alzheimer’s disease, specifically for dominantly inherited Alzheimer’s disease (DIAD), but the actual investigational products are not specified in the provided data.

The trial appears to be studying anti-amyloid treatments and their effects on disease biomarkers, but without specific medication names being provided, I cannot list and describe individual medications.

If you have additional information about the specific medications used in this trial, please provide it, and I will format the response accordingly with medication names in bold and their descriptions.

Dominantly Inherited Alzheimer’s Disease (DIAD) – A rare, genetically determined form of Alzheimer’s disease that is passed down through families in an autosomal dominant pattern. This condition typically causes symptoms much earlier than the common form of Alzheimer’s disease, often beginning in a person’s 30s or 40s. The disease progresses with the accumulation of abnormal proteins (beta-amyloid and tau) in the brain, leading to gradual changes in memory and thinking abilities. DIAD follows a predictable course in affected families, with symptoms typically appearing at about the same age in each generation. The condition affects multiple generations within a family, with each child of an affected parent having a 50% chance of inheriting the disease-causing mutation.